Vaxon Biotech
Records under this name other than patents Vaxon Biotech holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 6 of 6 · Back to Vaxon Biotech
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,663,645 | Use of native peptides and their optimized derivatives for vaccination Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,900,600 | Identification, optimization and use of cryptic HLA-A24 epitopes for immunotherapy Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,465,747 | Identification, optimization and use of cryptic HLA-B7 epitopes for immunotherapy Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,024,868 | Identification, optimization and use of shared HLA-B*0702 epitopes for immunotherapy Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 12,048,737 | Use of a Vaccine Targeting a Cryptic Tert Epitope, for Treating Cancer in a HLA-A*0201-Positive Patient Having a Non-Immunogenic Tumor Expressing Tert Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 7,973,128 | Immunogenic polypeptide composed of tumor antigen-derived optimized cryptic peptides, and uses thereof Formerly held In force Term ended Sep 30, 2026 · From the USPTO record | In force | Term ended Sep 30, 2026 | From the USPTO record |